A complementary drug to combat Alzheimer’s disease could target a specific part of the nerve cell protein tau. This is the finding of research from the University of Gothenburg, which also offers a ...
News Medical on MSN1h
Breakthrough discovery on tau protein opens new paths for Alzheimer’s drug developmentA complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau.
A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the ...
A London clinic has become the first in Europe to roll out two Alzheimer’s wonder drugs privately after they were rejected for NHS use. Lecanemab and donanemab received the green light from regulators ...
Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
One London clinic has become the first in Europe to offer the drug privately for an 'eye-watering' annual sum, after the NHS ...
Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...
Lecanemab and donanemab received the green light from regulators last year but the benefits were deemed "too small to justify the costs" to the health service. Re:Cognition Health, based on Harley ...
The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...
New drug approvals and a federal dementia care pilot program among the year's significant developments, according to the nonprofit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback